Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$127.08 USD
+2.83 (2.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $127.12 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$127.08 USD
+2.83 (2.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $127.12 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017
by Zacks Equity Research
We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.
Sarepta Appoints Ex-Allergan Executive as CEO and President
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased
Is the Options Market Predicting a Spike in Sarepta (SRPT) Stock?
by Zacks Equity Research
Investors in Sarepta Therapeutics, Inc. (SRPT) need to pay close attention to the stock based on moves in the options market lately.
Why Is Sarepta (SRPT) Down 2.7% Since the Last Earnings Report?
by Zacks Equity Research
Sarepta (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
by Zacks Equity Research
We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.
Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT) reported wider than expected loss in the fourth quarter of 2016.
Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
by Zacks Equity Research
Options traders are pricing in a big move for Sarepta Therapeutics (SRPT) shares as it has huge implied volatility.
Is a Surprise Coming for Sarepta Therapeutics (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
by Zacks Equity Research
Catabasis (CATB) announced disappointing top-line safety and efficacy data from part B of the MoveDMD study (phase I/II) on edasalonexent (CAT-1004).
Is BioMarin (BMRN) Well Poised for Growth in 2017?
by Zacks Equity Research
We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.
Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock?
by Zacks Equity Research
Investors in Sarepta Therapeutics (SRPT) need to pay close attention to the stock based on moves in the options market lately.
Not Too Late to Ride on Q4 Earnings: 3 Biotech Picks
by Zacks Equity Research
The biotech sector continues to witness a flurry of mergers and acquisitions and licensing deals.